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Peripheral and Local Human Papillomavirus
16–Specific CD8þ T-Cell Expansions Characterize
Erosive Oral Lichen Planus
Manuelle Viguier1,2,13, Herve´ Bachelez2,3,13, Be´atrice Poirier1, Je´re´my Kagan4,5,6,7, Maxime Battistella1,8,
Franc¸ois Aubin9, Antoine Touze´10, Maryvonnick Carmagnat11, Camille France`s12, Marie-Lise Gougeon1,4 and
Nicolas Fazilleau4,5,6,7,14
Erosive oral lichen planus (OLP) is a chronic, disabling mucocutaneous dysimmune rare disease characterized by
mucosal inflammatory erosive lesions with pathological evidence for a marked CD8þ cytotoxic T-lymphocyte
(CTL) infiltration. However, the specificity of lesional CTL in OLP has never been analyzed. To investigate the
molecular mechanisms underlying dysregulation of T-cell immune responses in patients with OLP, we studied the
diversity and antigen specificity of the TCR expressed by CD8þ T cells using dextramer staining, spectratyping,
and TCR sequencing in 10 OLP patients undergoing extracorporeal photochemotherapy. Expansions of TCRVb3-
bearing CD8þ T cells were found in peripheral blood and in lesional tissues of OLP patients. Spectratyping and
sequencing studies identified specific clonotypes in each patient. These expansions were enriched with human
papillomavirus 16 (HPV16)–specific CD8þ T cells in HLA-A*0201þ patients as shown by their immune recognition
of the E711-20 immunodominant epitope. Under treatment with extracorporeal photochemotherapy, clonotypic
CD8þ T-cell expansions decreased in parallel with clinical remission. Altogether, these data establish a link
between HPV infection and OLP pathogenesis by identifying a massive clonal expansion of CD8þ T cells with
increased frequency of HPV 16–specific CD8þ T cells in OLP patients.
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INTRODUCTION
Lichen planus is a chronic inflammatory disease of unknown
etiology involving the skin and/or mucous membranes,
leading to a variety of clinical presentations (Le Cleach and
Chosidow, 2012). Erosive oral lichen planus (OLP) is the most
prevalent subtype, affecting 0.1 to 4% of the general population,
and is characterized by a severely disabling course in its erosive
form that often requires immunomodulatory systemic therapies
such as oral steroids, immunosuppressants, and more recently
extracorporeal photochemotherapy (ECP) (Becherel et al., 1998;
Edwards and Kelsch, 2002; Guyot et al., 2007). Pathologically,
OLP is characterized by a predominant infiltration of immune
cells, mainly CD8þ cytotoxic T lymphocytes (CTLs), associated
with apoptosis of epithelial cells and disruption of the basement
membrane zone (Zhou et al., 2002). Similarly, the presence in
OLP lesions of CTL in the vicinity of damaged epithelial cells
supports the hypothesis that a dysregulated CTL response of
unknown antigen specificity has a key role in the pathogenesis
of the disease (Santoro et al., 2004).
However, the nature of these antigens remains controver-
sial. Indeed, although autoreactivity of lesional skin–derived
CTL against epithelial cells has been suggested in OLP patients
(Sugerman et al., 2000; Gorsky and Epstein, 2011; Syrjanen
et al., 2011), other studies identified the presence of DNA
from several human papillomavirus (HPV) subtypes in
mucosal lesions of OLP, raising the issue of the self versus
non-self nature of the target antigens in OLP (Jontell et al.,
1990; Young and Min, 1991; Miller et al., 1993; Lodi et al.,
2005; Yildirim et al., 2011). So far, the lack of any study using
accurate tools to address the specificity of lesional CTL in OLP
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precludes any conclusion about mechanisms underlying this
dysregulation. In this study, using dextramer, spectratyping, and
sequencing in 10 patients with severe erosive OLP, we investi-
gated the antigen specificity of the CD8þ T-cell expansions.
RESULTS AND DISCUSSION
TCRVb3þ clonal expansions alter CD8þ T-cell repertoires of
OLP patients at flare
To understand the molecular events that govern the physio-
pathology of OLP, we investigated the T-cell repertoire of 10
patients with OLP. At flare, the usage of each TCRVb gene
segment, as estimated by quantitative real-time reverse-tran-
scriptase–PCR in CD4þ and CD8þ peripheral blood T cells,
revealed striking predominance of the TCRVb3 gene segment
in CD8þ T cells (26.49±4.81%), whereas it was used at a
much lower level in the circulating CD4þ counterparts
(11.49±2.24%) or in both isolated CD4þ and CD8þ T cells
from healthy donors (Figure 1a). Results from quantitative
real-time reverse-transcriptase–PCR were confirmed by flow
cytometry, showing predominance of TCRVb3 expression in
the peripheral blood CD8þ T lymphocytes (data not shown,
17.27±4.51%).
The quantitative PCR products were further used for the
amplification of dye-labeled oligonucleotides specific for Cb
and allowed to assess the complementary determining region
3 (CDR3) length distribution. For each TCRVb gene segment
tested and for the TCRVb3 gene segment from CD4þ and
CD8þ T cells from healthy donors or from CD4þ T cells
isolated from OLP patients (Figure 1b), CDR3b length dis-
tribution profiles displayed Gaussian-like curves, the hallmark
of a polyclonal T-cell repertoire. In contrast, CDR3b distribu-
tion profiles of the TCRVb3 gene segment were altered with
single expansions in blood CD8þ T cells from all OLP
patients, as observed in OLP no. 5 for a CDR3b size of 11
amino acids (Figure 1b). Therefore, we determined the Vb-Jb
rearrangement corresponding to the observed clonal expan-
sion and further cloned and sequenced it. As shown in
Figure 1c, one single CDR3b sequence was found in each
patient. Furthermore, we revealed that similar TCRVb3þ
clonal expansions were also present in tissue lesions of three
 1 1.5 SFVIGGVSNPQ TGTGCCAGCAGTTTTGTCATTGGGGGGGTTAGCAATCAGCCCCAG
 2 2.7 SEPGQGFGEQTGTGCCAGCAGTGAACCGGGACAGGGTTTTGGTGAGCAG
 3 2.7 SIGLHYEQTGTGCCAGCAGTATAGGGCTCCACTACGAGCAG
 4 2.7 SLGVHYEQTGTGCCAGCAGTTTAGGTGTGCACTACGAGCAG
 5 2.2 SQGVFLGAGELTGTGCCAGCAGTCAAGGAGTCTTCCTGGGGGCCGGGGAGCTG
 6 2.1 SLLEGLAGVDEQ TGTGCCAGCAGTTTATTGGAGGGACTAGCGGGAGTGGATGAGCAG
 7 1.2 SYIGLQSKANYGYTGTGCCAGCAGTTATATAGGCCTACAGAGTAAAGCTAACTATGGCTAC
 8 2.7 SEPGQGFGEQTGTGCCAGCAGTGAACCGGGACAGGGTTTTGGTGAGCAG
 9 2.7 SFQPGGQTGTGCCAGCAGTTTCCAACCAGGGGGGCAG
 10 2.2 SLTTGELTGTGCCAGCAGTTTAACCACCGGGGAGCTG
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Figure 1. TCRVb3þ clonal expansions skewed peripheral and lesional CD8þ T-cell repertoires of oral lichen planus (OLP) patients at flare. (a) Reverse-
transcriptase–PCR (RT–PCR) amplifications of the TCRVb3 usage in CD4þ and CD8þ T cells from the blood of healthy donors (HDs) or OLP patients. PBMC,
peripheral blood mononuclear cell. (b) CDR3b length distributions for CD4þ and CD8þ Vb3-Cb rearrangements from a representative HD and a representative
OLP patient. The peak of the 11th codon is marked on the abscissa axis. (c) Table of CDR3 clonotypes identified in each OLP patient (nucleotidic and amino-acid
(AA) sequences). (d) CDR3b length distributions (left) and clonotype distribution estimated by sequencing (right) in lichen lesions in three representative OLP
patients (OLP nos. 2, 4, and 5). *Po0.05, **Po0.01.
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OLP patients (Figure 1d). Overall, neither CDR3b length nor
consensus sequence was shared across all OLP patients.
However, all detected CD8þ clonal expansions were using
the TCRVb3 gene segment, even in patients not sharing
common class I HLA alleles (Supplementary Table S1
online). Interestingly, 5 out of the 10 clonotypic TCRs were
composed of the Vb-Jb2.7 rearrangement, and one clonotypic
sequence was found in two different patients (OLP nos. 2 and
8; Figure 1c). Of note, flow cytometric characterization of
TCRVb3þCD8þ T cells in peripheral blood mononuclear
cells (PBMCs) confirmed their activated status as shown by
surface expression of HLA-DR (data not shown, 20.99±
4.52%, n¼7), CD38 (24.85±6.18%, n¼4), and perforin
content (15.2±4.54%, n¼ 7). Altogether, these data show
that clonotypic TCRVb3þCD8þ T-cell expansions are
detected in situ and in the blood of OLP patients at flare.
These sets of data extend previous observations reported in
two studies, one reporting the increased presence of TCRVb3-
and TCRVa2-positive cells in the oral mucosal T-cell infiltrate
of 7 OLP patients (Simark-Mattsson et al., 1994), and
the other performed in 12 OLP patients showing that CD8þ
T cells had skewed TCR repertoire toward the usage of a
restricted set of TCRVb segments including TCRVb3 (Gotoh
et al., 2008).
Tracking of CD8þTCRVb3þ clonal expansions following disease
activity in OLP patients
We next reasoned that the CD8þ clonal expansions could
actively participate in the physiopathology of OLP and tested
this hypothesis by performing a longitudinal study of the TCR
repertoire in all OLP patients. PBMCs were isolated at different
time points corresponding to distinct clinical status: flare
(before starting ECP), partial remission, complete remission
following ECP, and relapse after ECP withdrawal. For all
collected samples, TCRVb usage and CDR3b length distribu-
tion were performed as well as sequencing of Vb-Jb rearrange-
ments corresponding to the clonal expansions at flare
(Figure 1c). This allowed a follow-up of peaks corresponding
to TCRVb3þ clonal expansions in the T-cell compartment
(Figure 2 and Supplementary Figure S1 online). For three
patients (OLP nos. 5, 6 (Figure 2) and 8 (Supplementary Figure
S1 online)), we observed a disappearance of the peaks
corresponding to the TCRVb3þ clonal expansions that strictly
correlated with a clinical improvement (either partial remis-
sion or complete remission). However, for the seven remain-
ing OLP patients (as an example OLP no. 4, Figure 2), CDR3
distribution profiles were all disturbed irrespective of the
clinical status of the patients. Nevertheless, we found a strong
correlation between the clonotype usage and the clinical
status of OLP patients for 8 out of 10 patients. A pronounced
decrease or disappearance of the frequency of TCRVb3þ
clonotype was observed in OLP patients 1, 4, 5, 6, and 8,
whereas a slight decrease was found in OLP cases 2, 3, and 7
(Figure 2 and Supplementary Figure S1 online). Moreover, the
clonotype identified at initial flare was also found at high
frequency at the time of clinical relapse (OLP nos. 4, and 5
(Figure 2) and nos. 9 and 10 (Supplementary Figure S1
online)). Overall, these data support that clinical remission
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Figure 2. Decrease or disappearance of TCRVb3þ clonal expansions over the clinical course of the disease in oral lichen planus (OLP) patients. CDR3b length
distributions (left column) for different CD8þ Vb3-Jb rearrangements over the clinical course of the disease following extracorporeal photochemotherapy (ECP) and
clonotype distribution estimated by sequencing (right column) for three different representative OLP patients (OLP nos. 4, 5, and 6). CR, complete remission; PR,
partial remission.
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obtained with ECP in OLP is associated in most cases with a
decrease or disappearance of TCRVb3 clonotypic CD8þ
T-cell expansions, suggesting the pathogenic relevance of
these clonotypic expansions.
CD8þ T cells expressing clonal TCRVb3þ in OLP patients are
specific for HPV16
Lesional CTLs from OLP patients are suspected to recognize
an antigen associated with major histocompatibility complex
class I molecule on lesional keratinocytes (Sugerman et al.,
2000). Furthermore, several studies have shown the presence
of several HPV subtypes in mucosal OLP lesions (Jontell et al.,
1990; Young and Min, 1991; Miller et al., 1993; Lodi et al.,
2005; Yildirim et al., 2011). Detection of current or past HPV
infection could be performed in 6 out of our 10 patients either
on tissue biopsies or by serology. Three out of six OLP tested
patients were found HPV positive and, among them, HPV16
DNA and/or HPV16-specific IgG were found in 2 out of the 3
HPV-positive patients (OLP nos. 2 and 5). To test whether
TCRVb3þ clonal expansions might exhibit HPV specificity,
we stained PBMCs from the five HLA-A*0201þ OLP patients
of the cohort with peptide-containing major histocompatibility
complex class I dextramer. For all these patients, a distinct
population of CD8þ T cells expressing a TCRVb3 specific for
the E711-20 immunodominant peptide of HPV16 was detected,
as shown for OLP no. 2 at flare or OLP no. 4 under ECP
(Figure 3a; mean percentage of CD8þDext-HPVþ in
TCRVb3þCD3þ cells: 2.62±1.7%, n¼5). As expected,
almost no TCRVb3þ T cells were stained with HLA-A2/HIV-
p17 Gag dextramer in these HIV-negative patients (Figure 3a;
CD8þDext-HIVþ : 0.64±0.3%, n¼5). We then sorted out
HPV-specific CD8þ TCRVb3þ cells as well as their CD8þ
TCRVb3þ Dext-HPV- counterparts from OLP nos. 3, 4, and 7.
Spectratyping analysis and CDR3b sequencing were per-
formed, revealing a striking enrichment of Dext-HPVþ popu-
lations with the clonotype in contrast with Dext-HPV- subset
that showed no enrichment (Figure 3b). In the last series of
experiments, we performed in situ immunostaining on OLP
lesion from OLP no. 2. The presence of cells expressing CD3,
CD8, and the cytotoxic marker TIA1 (T-cell-restricted intra-
cellular antigen 1) were detected (Figure 4a), some of these
bearing TCR specific for HLA-A2/HPV E711-20 peptide,
whereas staining with the irrelevant Dext-HIV yielded nega-
tive results in the same patient (Figure 4b).
Overall, these data demonstrate that a notable proportion of
clonal CD8þ blood T cells of OLP patients are HPV16
specific, also infiltrating mucosal and/or skin lesions, and
decreasing or disappearing following clinical remission, sug-
gesting their pathogenic role in OLP. These results are
reminiscent of results from previous in vitro studies showing
the capacity of this E711-20 HPV16 epitope to favor the
stimulation and expansion of CTL clones expressing TCRVb3,
without evidence of HLA class I restriction (Nilges et al., 2003;
Schreurs et al., 2003). These sets of data also raise the HPV
infection status in OLP patients. Similarly, a large set of
published HPV detection studies support a pathogenic
contribution of some HPV subtypes in OLP (Gorsky and
Epstein, 2011; Syrjanen et al., 2011). Notably, detection of
viral DNA mainly derived from HPV6/11/16/31/33 has been
reported in mucosal oral and/or genital lesions from OLP
patients in several studies, providing a rationale for their role
as putative antigenic stimuli (Lodi et al., 2005; Mattila et al.,
2012). This latter hypothesis has been reinforced by a recent
exhaustive systematic review of HPV detection in 39 selected
cross-sectional studies, showing that HPV DNA is significantly
more frequently detected in OLP lesions compared with
controls (Syrjanen et al., 2011). Indeed, the positive detec-
tion of previous or current infection with HPV16 in 2/6
of our patients, including 1 patient who showed clear
expansion of HPV16 E711-20–specific cells in blood and
lesional mucosa, is a strong support for the contribution of
HPV as an antigenic stimulus of CTL expansion that
characterizes severe erosive OLP. Finally, the presence of
HPV16 E711-20–specific CD8
þ T cells in the vicinity of
dying epithelial cells in a studied patient correlates with
their potential involvement in tissue damage of OLP,
even though this latter observation does not rule out the
deleterious role of other subtypes than HPV16 that were not
addressed in our patients. As some of our patients did not
show either the presence of HPV16 DNA or the serological
evidence of previous HPV16 infection, it remains to be
determined whether other HPV subtypes or even alternative
viral agents would be able to trigger similar CTL expansions in
OLP (Lodi et al., 2005). Nevertheless, HPV serology is a poor
marker of current infection and HPV DNA detection can be
rendered difficult, as most HPV infections are transient (Ho
et al., 1998; Vaccarella et al., 2010).
As most adult individuals are infected at some point with
one or several HPV subtypes, the present results also raise the
mechanisms underlying dysimmunity in OLP patients. Sup-
porting the autoimmune hypothesis and its possible link with
HPV is the previously established presence among lesional T
lymphocytes of two OLP patients of CTL clones reacting
toward autologuous keratinocytes immortalized with HPV16
E6 and E7 (Sugerman et al., 2000). It is worth noticing that a
causal role for HPV infection in OLP does not necessarily
require constant tissue viral replication, as an initial viral
stimulation might be sufficient to trigger the founder immune
response, with following autoimmune T-cell expansions
related to molecular mimicry, unsequestration of masked
self epitopes, or both (Selmi et al., 2012). As such, it might
explain why we were able to detect antibodies to HPV16 in
the sera of only two patients of our cohort. In line with the
former of these hypotheses, molecular mimicry between
HPV16 E7 protein and human self has been revealed
by computer-based analyses, providing a rational basis for
further investigations of OLP lesional CTL regarding their
immunoreactivity toward HPV versus self-candidate antigens
(Natale et al., 2000). However, alternative mechanisms
such as alterations of the TCRVb3þ /HLA-peptide synapse by
some viral products cannot be ruled out. Finally, it also
remains to be determined whether HPV and/or other viral
stimuli are involved in other forms of lichen planus. Our data
also suggest that prophylactic HPV16 vaccine in addition to
preventing cervical dysplasia and cancer may also protect
against OLP.
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MATERIALS AND METHODS
Patients and healthy donors
Ten patients with OLP treated with ECP were enrolled. They consisted
of 8 women and 2 men (mean age: 56.5 years (range: 25–78))
(Supplementary Table S1 online). The characteristics of the eight
patients have been previously reported (Guyot et al., 2007). Previous
treatment with glucocorticoids and immunosuppressive agents was
stopped 4 weeks before ECP initiation. All patients reached remission
under ECP, either complete remission or partial remission (defined by
regression of lesions of at least 50%) (Guyot et al., 2007). Clinical
statuses were determined at the time of blood collection. The
Institutional Review Board (Comite´ de Protection des Personnes Ile
de France IV, 2009/10NI) approved the study that was qualified as
noninterventional. The patients were fully informed and had no
objection to participate in the study. Written patient consent was not
required because French law considers that it is not mandatory for
noninterventional biological collection for immunological and
molecular research, with the exception of genetic studies on
germinal DNA. Healthy donors were blood donors from the
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Figure 3. A subpopulation of peripheral CD8þ T cells from oral lichen planus (OLP) patients is human papillomavirus 16 (HPV16) specific and is enriched in
TCRVb3þ clonal expansions. (a) Flow cytometric detection using dextramer of HIV- and HPV-specific CD8þ T cells in CD3þ Vb3þ cells from the blood of two
representative HLA-A*0201þ OLP patients (OLP nos. 2 and 4). (b) CDR3b length distributions for Vb3-Cb rearrangements on unsorted T cells or isolated T cells
with HPV-Dextramer (left column) and clonotype distribution estimated by CDR3 sequencing (right column) for three different representative HLA-A*0201þ OLP
patients (OLP nos. 7, 3, and 4).
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Preparation of PBMCs
Blood was collected at baseline before any ECP treatment (‘‘flare’’)
and at several time points. PBMCs were prepared by Ficoll-Hypaque
density gradient centrifugation and cryopreserved in liquid nitrogen in
8% dimethylsulfoxide, 42% fetal calf serum, and 50% RPMI-1640
medium (Invitrogen, Carlsbad, CA).
Antibodies and flow cytometric analysis
Anti-CD3 FITC (Clone BW264/56, Miltenyi Biotec, Bergisch
Gladbech, Germany), anti-CD8-APC (SK1, BD Pharmingen, Franklin
Lakes, NJ), Dextramer-HPV E711-20-PE (Dext-HPV PE; HLA-A*0201;
YMLDLQPETT, Immudex, Copenhagen, Denmark), Dextramer-HIV-1
P17 Gag 77-85-PE (Dext-HIV-PE; HLA-A*0201, Bayport, MN;
SLYNTVATL, Immudex), and anti-TCR-Vb3-FITC (JOVI-3, Ancell,
Bayport, MN) were used. Cells were incubated with dextramer for
10 minutes at room temperature, and then antibodies were added for
30 minutes at 4 1C. Stained cells were washed with phosphate-
buffered saline/0.5% BSA/0.1% NaN3 and analyzed using a FACS-
Calibur flow cytometer (Becton Dickinson,Franklin Lakes, NJ).
Purification of T-lymphocyte subsets
Dead cells were removed using the MACS Dead Cell Removal kit
(Miltenyi Biotec). T cells were isolated using anti-CD8 or anti-CD4
antibody-coated immunomagnetic beads and stabilized in PrepPro-
tect buffer (Miltenyi Biotec). Cell purities exceeded 85%. CD3þ
CD8þTCRVb3þDext-HPVþ or Dext-HPV- populations were isolated
using a MoFlo Astrios cytometer cell sorter (Beckman Coulter,
Villepinte, France).
TCR repertoire analysis
RNA was extracted using RNAeasy kit (Qiagen, Venlo, The Netherlands)
either from sorted PBMCs or from total skin or mucosal OLP lesions
and reverse-transcribed into complementary DNA using Superscript II
(Invitrogen Life Technologies, Carlsbad, CA). Quantitative PCR
amplifications were performed with TaqMan Universal PCR Master
Mix (Applied Biosystems, Carlsbad, CA), TCRVb gene segment–
specific oligonucleotides, TCRCb-specific antisense primer, and a
fluorescent probe specific for the TCRCb gene segment (Fazilleau
et al., 2007).
Cloning and sequencing of CDR3b rearrangements
Vb-Jb PCR products were cloned in pCR 4Blunt TOPO vector
(Invitrogen Life Technologies). Sequencing reactions were performed
using the ABI PRISM Big Dye Terminator Reaction Kit (Applied
Biosystems). Reaction products were analyzed on an ABI 3130XL 16
capillaries (Applied Biosystems).
Detection of HPV subtypes
Tissue samples were obtained either atraumatically using a cytobrush
(DNAPAP Cervical Sampler; Digene, Qiagen) secondarily placed in
Cervical Specimen Transport Medium (Digene, Qiagen) or by tissue
biopsy secondarily frozen. DNA extraction was performed using the
QIAGEN BioRobot EZ1 with the EZ1 DNA Tissue Kit (Qiagen).
Human papillomavirus detection was performed using two highly
sensitive and specific assays combining a specific multiplex PCR with
DNA microarray primer extension as described previously (Schmitt
et al., 2006; Ruer et al., 2009). Multiplex PCR reactions were
performed for the amplification of a-HPV, b-HPV, g-HPV, and m-
HPV types, respectively. The assays were combined in one single
chip to detect 27 HPV types from genus a, 25 cutaneous HPV types
from genus b, 16 cutaneous HPV types from genus g, and one from
genus m. Following PCR amplification, 10ml of each reaction mixture
was analyzed using the Luminex technology (Luminex, Austin, TX).
The detection limit was determined using the cutoff of 10 median
reporter fluorescence intensity and varied between 100 and 800 pg of
PCR products (Schmitt et al., 2006). For each sample, three multiplex
CD3 CD8 TIA1
Dextramer HLA-A*0201
HIV-1 SLYNTVATL
Dextramer HLA-A*0201
HPV YMLDLQPETT
Figure 4. Human papillomavirus 16 (HPV16)–specific CD8þ T cells infiltrate lichen lesions. (a) The in situ immunostainings of CD3, CD8 (original magnification
200, scale bars¼ 100mm), and TIA-1 (T-cell-restricted intracellular antigen 1) (original magnification  400, scale bar¼50mm) on a biopsy taken from mucosal
lesions in oral lichen planus (OLP) patient no. 2. (b) The in situ immunostainings using either dextramer HIV-1 (left) or dextramer HPV (right) ( 630, scale
bars¼ 25mm; inset original magnification  1,000, scale bars¼10mm).
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PCR reactions were performed. Search for serum IgG antibodies against
HPV16 major capsid protein L1 was performed using ELISA (Combita
et al., 2002). Briefly, serum samples were tested in triplicate in a 1:20
dilution, and virus like particle-bound antibodies were detected using
anti-human IgG conjugated to peroxidase diluted at 1:20,000 (Southern
Biotech, Birmingham, AL). Cutoff value for positivity based on sample
from young children (mean reactivity plus 3 SD) was 0.2. Previously
tested samples were retested on the assay plate to confirm ensibility and
consistency of the assay (Ferguson et al., 2006).
In situ immunostaining
Acetone-fixed cryosections were incubated with dextramer for
75 minutes at room temperature and mounted with VECTASHIELD
Mouting Medium with 4’,6-diamidino-2-phenylindole (Vector
Laboratories, Burlingame, CA). Slides were studied using an Axiovert
200M microscope with MRm camera (Zeiss, Oberbochen, Germany).
Statistical analysis
Unpaired t-tests were calculated using Prism software (Irvine, CA).
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